title: The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
abstract: OBJECTIVE
  MegaFas Ligand (MFL) is a recombinant molecule that efficiently triggers apoptosis after binding to the Fas receptor expressed on target cells. The purpose of this study was to determine the potency of MFL in vitro and efficacy in vivo for intraperitoneal treatment of mice implanted with human ovarian carcinoma cells.
  
  
  METHODS
  The potency of MFL was compared to that of other Fas agonists in a cytotoxicity assay on SKOV-3 cells. The potency of MFL was further determined by measuring apoptosis in combination with cisplatin. The efficacy of MFL was determined in vivo using peritoneal xenograft models of human ovarian carcinoma.
  
  
  RESULTS
  In vitro, MFL induced significantly higher levels of apoptosis than other Fas agonists, and was able to overcome the resistance of the ovarian cancer cell line SKOV-3 to Fas agonist antibody. MFL exerted an enhanced cytotoxic effect when combined with platinum-based drugs, leading to significantly more apoptosis than by incubation with MFL or these drugs alone. Treatment of mice xenografted with SKOV-3 and HOC79 ovarian tumors by intraperitoneal administration of MFL alone or in combination with cisplatin resulted in a significant decrease in peritoneal tumor nodules and ascitic cells, and prolongation of survival as compared to non-treated mice. The beneficial effects of MFL treatment occurred in the absence of severe toxicity.
  
  
  CONCLUSIONS
  MFL is a novel pro-apoptotic molecule that is able to efficiently induce apoptosis in ovarian cancer cells as well as to potentiate the activity of chemotherapeutic agents in vitro and in vivo.
authors.affiliation: Apoxis SA, Preclinical Oncology, avenue de Sévelin 18, CH-1004 Lausanne, Switzerland.
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Etter
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bassi
authors.forename: Stéphane
authors.initials: S
authors.lastname: Germain
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Delaloye
authors.forename: Jürg
authors.initials: J
authors.lastname: Tschopp
authors.forename: Bernard
authors.initials: B
authors.lastname: Sordat
authors.forename: Marc
authors.initials: M
authors.lastname: Dupuis
mesh_terms: D052242:Adiponectin / Q000737:chemistry; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D003094:Collagen / Q000737:chemistry; D004341:Drug Evaluation; D053222:Fas Ligand Protein / Q000737:chemistry*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017434:Protein Structure, Tertiary; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D052242:Adiponectin; D053222:Fas Ligand Protein; D011993:Recombinant Fusion Proteins; D003094:Collagen; D002945:Cisplatin